Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
NEPH

Nephros Inc

NEPH

2.19USD+0.11 (+5.29%)Market Closed
Watchlist

Market Summary

USD2.19+0.11
Market Closed
5.29%

NEPH Stock Price

View Fullscreen

NEPH RSI Chart

NEPH Valuation

Market Cap

23.0M

Price/Earnings (Trailing)

-4.91

Price/Sales (Trailing)

1.51

Price/Free Cashflow

25.22

NEPH Price/Sales (Trailing)

NEPH Profitability

Return on Equity

-54.24%

Return on Assets

-42.83%

Free Cashflow Yield

3.97%

NEPH Fundamentals

NEPH Revenue

Revenue (TTM)

10.0M

NEPH Earnings

Earnings (TTM)

-4.7M

Earnings Y/Y

61.92%

Earnings Q/Q

-41.5%

Price Action

Last 7 days

-0.9%

Last 30 days

9.0%

Last 90 days

34.4%

Trailing 12 Months

106.4%

How does NEPH drawdown profile look like?

NEPH Financial Health

Current Ratio

4.65

NEPH Investor Care

Shares Dilution (1Y)

1.76%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20229.7M10.3M10.2M10.0M
20218.8M9.5M9.9M10.3M
20200008.6M
20190000
20180000
20172.5M2.8M3.3M0
20162.0M1.9M2.1M2.3M
20151.8M1.9M1.8M1.9M
20141.7M1.6M1.6M1.7M
20131.8M2.1M1.9M1.7M
20122.1M1.7M1.9M1.8M
20112.6M2.5M2.2M2.2M
20102.7M2.8M2.9M2.9M
20090002.7M

Latest Insider Trading transactions for NEPH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 15, 2023
banks robert r. jr.
bought
3,206
1.6869
1,901
president and ceo
Aug 14, 2023
banks robert r. jr.
bought
148
1.5
99.00
president and ceo
Jan 05, 2023
harris joseph michael
acquired
-
-
8,402
-
Jan 05, 2023
amron arthur h
acquired
-
-
27,613
-
Jan 05, 2023
lask alisa
acquired
-
-
27,613
-
Jan 05, 2023
gwydir tom
acquired
-
-
27,613
-
Jan 05, 2023
spandow oliver j.
acquired
-
-
42,481
-
Mar 05, 2022
astor andrew
acquired
40,000
2.7
14,815
president, ceo & cfo
Feb 16, 2022
lobo wesley s.
sold (taxes)
-30,667
4.8
-6,389
chief marketing officer
Dec 14, 2021
gwydir tom
acquired
-
-
4,582
-

1–10 of 50

Which funds bought or sold NEPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 15, 2023
MORGAN STANLEY
unchanged
-
-1,071
22,632
-%
Nov 14, 2023
STATE STREET CORP
unchanged
-
-863
23,469
-%
Nov 14, 2023
Tower Research Capital LLC (TRC)
reduced
-59.21
-525
334
-%
Nov 14, 2023
WEXFORD CAPITAL LP
added
0.82
-211,663
5,457,410
1.21%
Nov 14, 2023
VANGUARD GROUP INC
added
3.9
-2,008
252,654
-%
Nov 14, 2023
Royal Bank of Canada
sold off
-100
-
-
-%
Nov 14, 2023
JPMORGAN CHASE & CO
new
-
12.00
12.00
-%
Nov 14, 2023
RENAISSANCE TECHNOLOGIES LLC
sold off
-100
-21,000
-
-%
Nov 13, 2023
WELLS FARGO & COMPANY/MN
added
3.03
-1.00
101
-%
Nov 13, 2023
ELKHORN PARTNERS LIMITED PARTNERSHIP
unchanged
-
-3,000
67,000
0.04%

1–10 of 20

Latest Funds Activity

Are funds buying NEPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NEPH
No. of Funds

Schedule 13G FIlings of Nephros Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 03, 2023
cowen prime advisors llc
-
0
SC 13G
Feb 03, 2023
cowen prime advisors llc
-
0
SC 13G
Feb 03, 2023
cowen prime advisors llc
4.00%
1,431,404
SC 13G
Jan 06, 2023
intelligent fanatics capital management llc
0%
0
SC 13G/A
Feb 28, 2022
intelligent fanatics capital management llc
5.12%
525,408
SC 13G
Feb 09, 2022
cowen prime advisors llc
6%
633,050
SC 13G
Feb 08, 2022
samjo capital llc
4.2%
425,000
SC 13G/A
Jun 11, 2021
evans daron
4.7%
478,874
SC 13D/A
Jan 27, 2021
cowen prime services llc
6%
575,077
SC 13G
Oct 26, 2020
wexford capital lp
36.78%
6,664
SC 13D/A

Recent SEC filings of Nephros Inc

View All Filings
Date Filed Form Type Document
Nov 08, 2023
10-Q
Quarterly Report
Nov 06, 2023
8-K
Current Report
Nov 03, 2023
4
Insider Trading
Nov 03, 2023
3
Insider Trading

Peers (Alternatives to Nephros Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.9B
40.0B
10.31% -2.25%
35.24
4.55
-11.26% -34.57%
71.3B
19.4B
-9.23% -5.96%
44.09
3.79
2.66% -16.58%
18.3B
15.0B
6.14% -30.83%
7.06
1.22
3.01% 209.09%
16.9B
3.8B
14.26% 16.16%
46.7
4.45
-1.48% -28.97%
MID-CAP
9.3B
12.7B
13.37% -11.57%
21
0.74
0.68% -30.25%
8.9B
2.7B
-0.34% -27.61%
-55.55
3.25
-3.01% 97.36%
8.4B
3.4B
1.77% 17.97%
29.76
2.43
3.13% 18.17%
6.8B
3.9B
15.17% 5.28%
-30.97
1.72
-2.62% 73.28%
2.9B
342.6M
7.33% -13.77%
-240.35
8.4
42.19% 84.14%
2.5B
6.6B
-12.19% -8.47%
12.51
0.38
2.61% 0.62%
SMALL-CAP
1.1B
3.1B
27.38% -62.38%
-2.62
0.36
7.95% -550.16%
328.7M
163.3M
8.29% -28.40%
-13.38
2.01
7.14% -56.09%
279.9M
335.9M
9.78% -43.73%
43.42
0.83
4.71% 116.39%
73.4M
50.3M
2.42% 10.99%
-4.85
1.46
3.23% 20.81%
5.0M
3.8M
4.66% -47.56%
-0.43
1.32
17.30% 10.67%

Nephros Inc News

Latest updates
Simply Wall St11 Nov 202302:44 pm29 days ago
GlobeNewswire01 Nov 202307:00 am40 days ago
Nairametrics08 May 202207:00 am19 months ago
InvestorIdeas.com30 Aug 201806:22 pm5 years ago
MarketWatch17 Oct 201709:58 pm6 years ago
Seeking Alpha20 Jul 201707:00 am6 years ago
Mass Device22 Jul 201107:00 am12 years ago

Financials for Nephros Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q4
Revenue4.9%2,526,5002,409,0002,884,0002,187,0002,675,0002,578,0002,266,0002,736,0002,334,0002,121,0001,577,0002,529,0002,107,6671,686,3331,265,000843,667422,3331,0001,000306,000611,000
Gross Profit98.8%1,515,000762,0001,395,0001,053,0001,441,0001,360,0001,275,0001,587,0001,302,0001,225,000895,0001,491,0001,900,0001,819,0001,367,000998,000954,000952,000830,000467,000788,000
Operating Expenses8.1%2,208,0002,043,0002,209,0002,600,0001,959,0002,162,0002,392,0002,605,0002,021,0002,157,0002,493,0002,517,0002,191,0002,514,0002,235,0002,299,0001,683,0001,463,0001,483,0001,590,0001,191,000
  S&GA Expenses2.6%1,787,5001,743,0001,885,0002,177,0001,723,0001,718,0001,854,0001,999,0001,362,0001,544,0001,610,0001,950,0001,426,0001,787,0001,403,0001,503,0001,097,0001,069,0001,091,0001,260,000894,000
  R&D Expenses42.3%358,500252,000273,000372,000194,000395,000487,000556,000609,000751,000836,000563,000764,000777,000793,000756,000-352,000---
EBITDA Margin-------0.43-0.45-0.48-0.49-0.33-0.29-0.27-0.29-0.35-0.42-0.48-0.54----
Interest Expenses-25.0%3,0004,0006,0007,0007,00010,00011,00013,00015,00022,00030,00043,00055,00048,00046,00046,00026,00032,00028,00086,00084,000
Income Taxes-----37,0007,00014,00021,0001,000-10,00011,000-229,000----100,0004,000-3,000-1,795,000
EBT Margin-------0.45-0.48-0.52-0.53-0.36-0.33-0.31-0.33-0.39-0.46-0.53-0.60----
Net Income78.1%-706,500-3,231,000-1,137,000-1,967,000-922,500-1,222,000-1,126,000-537,000-759,000-1,012,000-1,657,000-1,098,000-144,000-744,000-942,000-1,349,000-725,000-566,000-682,000-1,429,0001,289,000
Net Income Margin-2.7%-0.71-0.69-0.50-0.54-0.37-0.36-0.36-0.45-0.53-0.42-0.36-0.27-0.31--------
Free Cashflow-14.7%-195,000-170,000-1,175,000-1,831,000-335,000-923,000-117,000-78,000-1,526,000-1,830,000-1,946,000-1,840,000364,000--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets5.1%10,91910,38610,92710,99911,33514,95315,52817,65017,82017,99117,93618,51015,24216,64918,29411,62911,55412,01410,13810,5589,404
  Current Assets7.5%8,5067,9148,3248,2619,11811,12211,65713,63413,62114,84014,66715,15411,75513,07014,8098,2998,1178,4377,1728,1738,376
    Cash Equivalents13.8%4,6224,0603,8363,6343,9404,1795,4216,9737,3508,2788,1638,2495,1557,0468,9624,1663,8554,3183,6084,5815,322
  Inventory6.7%2,2682,1262,3483,1533,4884,6644,6794,4624,6495,0874,6795,3045,3854,7693,6492,5622,1282,3142,0401,8641,459
  Net PPE-10.2%88.0098.0010711612845038472.0038230331129530229676.0081.0085.0089.0097.0091.0020.00
  Goodwill0%759759759800759800800759759759759759759759759759759759759748-
Liabilities32.7%2,2971,7312,0332,1181,7542,4722,1262,9012,4903,0002,3992,9373,8024,3734,6583,9404,8325,2084,5343,7602,337
  Current Liabilities52.7%1,8281,1971,4151,4121,5512,1111,7482,3901,8232,1701,4081,3252,3792,7653,1082,4283,1163,2923,1102,6541,440
Shareholder's Equity-0.4%8,6228,6558,8945,5926,30212,48113,40214,74915,33014,99115,53715,57311,44012,27613,6367,6896,7226,8065,6046,7984,067
  Retained Earnings-0.1%-143,800-143,600-143,100-142,831-141,983-138,800-137,692-135,725-134,683-133,500-132,395-131,858-131,100-130,087-128,430-127,332-127,188-126,444-125,502-124,153-123,489
  Additional Paid-In Capital0.1%152,364152,215152,021148,413148,275148,040147,781147,346146,883145,378144,801144,296139,410139,243138,953131,934130,830130,169127,974127,873127,419
Shares Outstanding0%10,48510,48510,48510,29710,30410,29910,21410,25810,0459,9439,8839,8739,0408,9868,5908,0597,4097,2597,1307,1856,751
Minority Interest----3,2893,2793,2603,2423,0543,0543,0543,0533,0513,0523,0463,0403,0143,0093,0033,0003,000-
Cashflow (Last 12 Months)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations148.7%562,000226,000276,000-195,000-170,000-1,072,000-1,797,000-335,000-910,000-117,000-55,000-1,526,000-1,817,000-1,720,000-1,840,000364,000-614,000-1,329,000-697,000-528,000-1,122,000
  Share Based Compensation-23.2%149,000194,000319,000179,000254,000277,000272,000434,000268,000281,000276,000206,000172,000179,000222,000670,000354,000150,000158,000397,000120,000
Cashflow From Investing-------103,000-34,000--62,000--23,000--13,000----14,000--137,000--
Cashflow From Financing100.0%--2,000-74,000-111,000-69,000-67,000281,000-37,00046,000231,000-3,0004,615,000-65,00028,0006,638,000-55,000171,0002,038,000-137,000778,0002,960,000

NEPH Income Statement

2023-09-30
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net revenue:    
Total net revenues$ 3,742$ 2,409$ 10,984$ 7,417
Cost of goods sold1,5481,6474,6004,195
Gross margin2,1947626,3843,222
Operating expenses:    
Selling, general and administrative2,1371,7436,5005,806
Research and development205252665896
Depreciation and amortization5548163162
Total operating expenses2,3972,0437,3286,864
Operating loss from continuing operations(203)(1,281)(944)(3,642)
Other (expense) income:    
Interest expense(4)(1)(17)
Interest income114367
Other income (expense), net1031(12)94
Total other expense:21312384
Loss from continuing operations(182)(1,250)(921)(3,558)
Net loss from discontinued operations(1,904)(2,700)
Net loss(182)(3,154)(921)(6,258)
Less: Undeclared deemed dividend attributable to noncontrolling interest(77)(206)
Net loss attributable to Nephros, Inc. shareholders$ (182)$ (3,231)$ (921)$ (6,464)
Net loss per common share, basic from continuing operations$ (0.02)$ (0.12)$ (0.09)$ (0.35)
Net loss per common share, diluted from continuing operations(0.02)(0.12)(0.09)(0.35)
Net loss per common share, basic from discontinued operations(0.18)(0.26)
Net loss per common share, diluted from discontinued operations(0.18)(0.26)
Net loss per common share, basic(0.02)(0.30)(0.09)(0.61)
Net loss per common share, diluted(0.02)(0.30)(0.09)(0.61)
Net loss per common share, basic, attributable to continuing noncontrolling interest(0.01)(0.02)
Net loss per common share, diluted, attributable to continuing noncontrolling interest(0.01)(0.02)
Net loss per common share, basic, attributable to Nephros, Inc, shareholders(0.02)(0.31)(0.09)(0.63)
Net loss per common share, diluted, attributable to Nephros, Inc, shareholders$ (0.02)$ (0.31)$ (0.09)$ (0.63)
Weighted average common shares outstanding, basic10,460,86610,303,81810,352,10810,278,258
Weighted average common shares outstanding, diluted10,460,86610,303,81810,352,10810,278,258
Comprehensive loss:    
Net loss$ (182)$ (3,154)$ (921)$ (6,258)
Other comprehensive loss, foreign currency translation adjustments, net of tax(3)
Comprehensive loss(182)(3,154)(921)(6,261)
Comprehensive loss attributable to noncontrolling interest(77)(206)
Comprehensive loss attributable to Nephros, Inc. shareholders(182)(3,231)(921)(6,467)
Product [Member]    
Net revenue:    
Total net revenues3,7132,39910,9127,387
Royalty and Other Revenues [Member]    
Net revenue:    
Total net revenues$ 29$ 10$ 72$ 30

NEPH Balance Sheet

2023-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 4,622$ 3,634
Accounts receivable, net1,4431,286
Inventory2,2683,153
Prepaid expenses and other current assets173188
Total current assets8,5068,261
Property and equipment, net88116
Lease right-of-use assets750984
Intangible assets, net392423
Goodwill759759
License and supply agreement, net301402
Other assets12354
TOTAL ASSETS10,91910,999
Current liabilities:  
Current portion of secured note payable71
Accounts payable805740
Accrued expenses712285
Current portion of lease liabilities311316
Total current liabilities1,8281,412
Equipment financing, net of current portion1
Lease liabilities, net of current portion469705
TOTAL LIABILITIES2,2972,118
COMMITMENTS AND CONTINGENCIES (Note 14)
STOCKHOLDERS’ EQUITY  
Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022.
Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2023 and December 31, 2022; 10,484,932 and 10,297,429 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively.1010
Additional paid-in capital152,364148,413
Accumulated deficit(143,752)(142,831)
Subtotal8,6225,592
Noncontrolling interest3,289
TOTAL STOCKHOLDERS’ EQUITY8,6228,881
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 10,919$ 10,999
NEPH
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
 CEO
 WEBSITEwww.nephros.com
 EMPLOYEES27

Nephros Inc Frequently Asked Questions


What is the ticker symbol for Nephros Inc? What does NEPH stand for in stocks?

NEPH is the stock ticker symbol of Nephros Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nephros Inc (NEPH)?

As of Fri Dec 08 2023, market cap of Nephros Inc is 22.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEPH stock?

You can check NEPH's fair value in chart. The fair value of Nephros Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nephros Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nephros Inc a good stock to buy?

The fair value guage provides a quick view whether NEPH is over valued or under valued. Whether Nephros Inc is cheap or expensive depends on the assumptions which impact Nephros Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEPH.

What is Nephros Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, NEPH's PE ratio (Price to Earnings) is -4.91 and Price to Sales (PS) ratio is 1.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nephros Inc's stock?

In the past 10 years, Nephros Inc has provided 0.179 (multiply by 100 for percentage) rate of return.